Novoxel Inc. and GPOphtho announce their agreement to expand access to Novoxel’s innovative Tixel device family across the United States. This collaboration aims to deliver breakthrough dry eye treatments and aesthetic procedures to eyecare physicians nationwide.
The agreement grants GPOphtho’s network of ophthalmologists and optometrists discounted pricing and value-added packages for Novoxel’s Tixel devices.
Tixel i® is specifically designed to treat Meibomian Gland Dysfunction (MGD), offering a fast and targeted solution for both upper and lower eyelids. A recent clinical trial (Sanni, et al, 2025) concluded that Tixel i is a safe, non-pharmacologic, first-line treatment for MGD. “What sets Tixel i apart from other dry eye treatments is that it only takes 2 minutes for both eyes to be treated. Unlike older technology, Tixel i safely treats upper and lower eyelids to maximize improvement,” says Cynthia Matossian, MD, FACS, and CEO of GPOphtho.
The FDA-cleared family of products provide year-round treatments for all skin types and age groups. They offer non-invasive rejuvenation without needles, bleeding, or pain, minimal downtime, no expensive consumables, and are radiation-free.
“Eyecare physicians are uniquely positioned to incorporate aesthetic procedures into their practices due to their expertise in the periocular anatomy and their familiarity with ophthalmic laser technology,” says Cynthia Matossian, MD, FACS, and CEO of GPOphtho. This agreement will enable eyecare professionals to easily integrate both functional and cosmetic procedures, creating new revenue streams and enhancing patient satisfaction.
Both Novoxel and GPOphtho are committed to bringing innovative, cutting-edge technology to more patients and practices across the US.
